Dental Bone Graft Substitutes Market is Expected to Reach $1.8 billion | MarketsandMarkets™
May 17, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 17, 2024 (GLOBE NEWSWIRE) -- Dental Bone Graft Substitutes market in terms of revenue was estimated to be worth $1.3 billion in 2024 and is poised to reach $1.8 billion by 2029, growing...
Gorilla Technology Releases Full Year Audited Financials for 2023
May 17, 2024 08:00 ET
|
Gorilla Technology Group Inc.
LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Gorilla Technology Group Inc. (NASDAQ: GRRR) ("Gorilla" or the “Company”), a global solution provider in Security Intelligence, Network Intelligence,...
Effnetplattformen Holding AB (publ): Delårsrapport Januari - mars 2024
May 17, 2024 02:30 ET
|
Effnetplattformen Holding AB
Stockholm, 17 maj 2024 -- Effnetplattformen Holding AB (publ) DELÅRSRAPPORT Januari - mars 2024 Koncernens omsättning för perioden januari – mars 2024 uppgick till KSEK 1 234 (4 456) eller SEK...
Clean Motion AB delårsredogörelse för januari-mars 2024
May 16, 2024 16:10 ET
|
Clean Motion AB
Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på...
Cancer Biomarkers Market is Expected to Reach $42.0 billion | MarketsandMarkets™
May 16, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 16, 2024 (GLOBE NEWSWIRE) -- Cancer Biomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR...
Oligonucleotide Synthesis Market is Expected to Reach $19.7 billion | MarketsandMarkets™
May 15, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 15, 2024 (GLOBE NEWSWIRE) -- Oligonucleotide Synthesis market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at...
PRANEŠIMAS DĖL UAB „ORKELA“ FINANSINĖS ATASKAITOS UŽ 3 MĖNESIŲ LAIKOTARPĮ, PASIBAIGUSĮ 2024 M. KOVO 31 D.
May 15, 2024 07:55 ET
|
ORKELA, UAB
Pagrindiniai duomenys apie Bendrovę UAB „Orkela“ (toliau – Bendrovė) yra uždaroji akcinė bendrovė, įregistruota VĮ „Registrų centras“ 2015 m. rugsėjo 24 d. Buveinės adresas: Jogailos g. 4 ,...
Notice Regarding Uab „orkela“ Financial Statements for 3-Month Period Ended 31 March 2024
May 15, 2024 07:55 ET
|
ORKELA, UAB
Basic data about the Company UAB „Orkela“ (hereinafter – the Company) is a private limited liability company registered with the State Enterprise Centre of Registers on 24 September 2015. ...
Už 2024 m. 3 mėn. laikotarpį tarpinis pranešimas: tęsiama Žaliųjų pajėgumų Portfelio plėtra
May 15, 2024 02:03 ET
|
AB Ignitis grupė
AB „Ignitis grupė“ (toliau – Grupė) publikuoja už 2024 m. 3 mėn. laikotarpį tarpinį pranešimą, kuris pridėtas prie šio pranešimo, bei skelbia, kad Grupės Koreguotas EBITDA siekė 181,7 mln. Eur (+21,2...
First three months 2024 interim report: continued Green Capacities Portfolio growth
May 15, 2024 02:03 ET
|
Ignitis grupė
AB “Ignitis grupė” (hereinafter – the Group) publishes its first three months 2024 interim report, which is attached to this notice, and announces that the Group’s Adjusted EBITDA amounted to EUR...